TiGenix IPO Prices in Brussels

TiGenix NV, a Belgium based regenerative medicine company with a cartilage repair product in Phase III trials, priced eight million shares at Euro 5 per share, for an IPO take of approximately Euro 40 million. It has raised over $36 million in VC funding since its 2000 inception, from firms like Auriga Partners, Capricorn Venture Partners, Fortis Private Equity, Gemma Frisius Fonds, HSS Ventures, Partners @Venture and Societe Regtionale d'Investissement de Wallonie. www.tigenix.com